At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNXT RenovoRx Inc
Trading 05-23 13:46:56 EDT
1.38
+0.00
0.00%
High1.39
Low1.35
Vol11.12K
Open1.36
D1 Closing1.38
Amplitude2.90%
Mkt Cap33.05M
Tradable Cap32.41M
Total Shares23.95M
T/O15.21K
T/O Rate0.05%
Tradable Shares23.49M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.